Sector News

Illumina acquires Conexio Genomics

January 27, 2016
Life sciences

(GenomeWeb) – Illumina announced today that it has acquired Australian HLA typing solutions provider Conexio Genomics.

Terms of the deal were not disclosed.

Illumina first partnered with Conexio in March 2015 to offer the TruSight HLA Solution, a sequencing-based product for accurate HLA typing across thousands of known and novel HLA alleles. The product uses Conexio’s Assign software for analysis and reporting.

The acquisition will enable Illumina to develop NGS-based transplant diagnostics assays, including a new solution for interrogating genomic variants in the gamma genomic block of the major histocompatibility complex, the company said in a statement.

“The addition of Conexio products and people solidify our HLA capabilities and demonstrate Illumina’s ongoing commitment to HLA and ultimately to the field of transplant science,” Alex Lindell, Illumina’s associate director of market development for HLA, said in the statement.

Conexio’s NGS development programs will be folded into Illumina’s existing business units.

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.